$CRL

Creamer Victoria L sold $1.1M of CRL

Creamer Victoria L (EVP & Chief People Officer) sold 4,179 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $259.16 ($1.08M total) on 2026-08-06.

Original reporting
SEC EDGAR · Creamer Victoria L
Published Aug 10, 2026, 8:35 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 8:53 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CRL
Neutral
medium confidence
Mentioned
$CRL
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRLNeutralLow
01

Why it matters

The newest disclosed fact is the specific open-market sale by an EVP and Chief People Officer, including share count, price, and post-transaction holdings.

02

Market read

Traders may note the insider sale for sentiment, but there is no accompanying operational or financial update in the text.

03

What to watch

The article does not state whether the sale was part of a broader pattern, nor does it provide context like option exercises, tax planning, or other concurrent transactions.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-10 after-hours; reflects sale dated 2026-08-06

Background

The article is a SEC Form 4 insider transaction disclosure for Charles River Laboratories International, Inc.

Company-level read

Ticker impact

$CRLNeutralMedium confidence
Context

Charles River Laboratories insider Victoria L Creamer sold 4,179 shares for about $1.08M at $259.16/share via an open-market sale.

Expected impact

Likely limited near-term impact; any effect is more about sentiment than new company fundamentals.

Evidence & confidence

The filing discloses transaction size, price, and post-sale holdings, but provides no accompanying corporate news, guidance, or operational catalyst.

Market effects

No clear sector read-through from a single routine insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification or personal liquidity needs, so the signal may be noise rather than bearish information.

Key entities

  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

    Subject of the Form 4 insider transaction disclosure.

  • Creamer Victoria L

    EVP & Chief People Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ACBHighAI 8/10

Aurora Snipes Back At Curaleaf’s Hostile Bid

Aurora Cannabis rejected Curaleaf's hostile $4 per share bid, urging shareholders to take no action. Curaleaf claims its offer represents a 45% premium over Aurora's 30-day average share price. Aurora's shares rose 34% to $3.89, while Curaleaf's OTC shares gained 6% to $9.80. Aurora's board formed a special committee to review the offer, which expires on December 1.

$AMLXHighAI 8/10

Biotech Stocks At 52-Week Highs - AMLX +63% With Phase 3 Data, VOGX +25%, OBIO +19%, ATRC, CRL

Several biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.

$CRLMed

Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript

Charles River Laboratories (CRL) reported Q2 2026 results, citing a strengthening biopharmaceutical demand environment. DSA net book-to-bill rose to nearly 1.2x for a third straight quarter above 1x. Organic revenue growth returned to 0.1%. Operating margin improved 420 bps sequentially to 20.5% after divestitures. CRL also announced collaborations with Eli Lilly (TuneLab) and Arovella Therapeutics (NGS).

$CRLMed

Charles River Laboratories International (CRL) Cuts Guidance, Is It Still Undervalued?

Charles River Laboratories International (CRL) cut its 2026 GAAP earnings guidance and reported a quarterly net loss, citing divestiture-related charges and slightly lower revenue year over year. The article notes strong recent share performance and presents two valuation views, including a $313.61 fair value versus a $267.49 last close, plus a planned $510M acquisition of K.F. (Cambodia) Ltd.

$CRLMed

Charles River (CRL) Lifts Adjusted EPS Outlook After DSA Beat and Divestiture Hit Has The Bull Case Changed?

Charles River Laboratories (CRL) reported Q2 2026 revenue of $1,004.08M and a GAAP net loss of $1.48M. The company cut 2026 GAAP EPS guidance to $3.05 to $3.35 per share due to divestiture-related losses, but raised full-year adjusted (non-GAAP) EPS after DSA results beat expectations, citing margin potential and lower non-human primate sourcing costs.